Login / Signup
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations.
Paulina Elena Stürzebecher
Ulrich Laufs
Published in:
Current opinion in lipidology (2024)
PCSK9 inhibitors are safe, well tolerated, and effective in primary and secondary prevention in a wide range of patient populations.
Keyphrases
</>
case report
low density lipoprotein